Overview

AMG 151 Amgen Protocol Number 20100761

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. AMG 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Metformin